Old Web
English
Sign In
Acemap
>
authorDetail
>
Mark I L Watling
Mark I L Watling
UCB
Gastroenterology
Placebo
Internal medicine
Medicine
Physical therapy
3
Papers
121
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis: Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Transcriptomics from a Phase 2a Randomized, Multicenter Double-Blinded Study.
2021
British Journal of Dermatology
Ruth Oliver
James G. Krueger
Sophie Glatt
Pavan Vajjah
C Mistry
M. Page
H. Edwards
Sandra Garcet
Xuan Li
B Dizier
Ash Maroof
Mark I L Watling
A El Baghdady
Dominique Baeten
Lucian Ionescu
Stevan Shaw
Show All
Source
Cite
Save
Citations (0)
Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study
2019
Annals of the Rheumatic Diseases
Sophie Glatt
Peter C. Taylor
Iain B. McInnes
Georg Schett
Robert Landewé
Dominique Baeten
Lucian Ionescu
Foteini Strimenopoulou
Mark I L Watling
Stevan Shaw
Show All
Source
Cite
Save
Citations (14)
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation
2018
Annals of the Rheumatic Diseases
Sophie Glatt
Dominique Baeten
Terry Baker
Meryn Griffiths
Lucian Ionescu
Alastair David Griffiths Lawson
A. Maroof
Ruth Oliver
Serghei Popa
Foteini Strimenopoulou
Pavan Vajjah
Mark I L Watling
Nataliya Yeremenko
Pierre Miossec
Stevan Shaw
Show All
Source
Cite
Save
Citations (107)
1